Tomita Natsuo, Kodaira Takeshi, Tachibana Hiroyuki, Nakamura Tatsuya, Mizoguchi Nobutaka, Takada Akinori
Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Radiother Oncol. 2009 Feb;90(2):231-5. doi: 10.1016/j.radonc.2008.12.004. Epub 2009 Jan 8.
The aim of this study was to evaluate the efficacy of radiation therapy (RT) for early-stage mucosa-associated lymphoid tissue (MALT) lymphoma.
Patients with stage IotaE (n=48) and stage capital PE, CyrillicE (n=2) MALT lymphoma treated with RT were reviewed. The primary tumor originated in the stomach in 20 patients, in the orbit in 9 patients, in the conjunctiva or eyelid and the parotid glands in 6 patients each, and 9 patients in the others. The median total RT dose was 32Gy (range, 25.6-50Gy). The median follow-up time was 50 months.
Although disease did not recur in the RT field in any patient regardless of the total dose, disease recurred outside the RT field in the seven patients. As all recurrences were localized, salvage RT was performed for each recurrence and achieved complete response without recurrence in the field. The 5-year overall survival, local control, and progression-free survival rates were 96.6%, 100%, and 82.2%, respectively.
A total dose of 25-30Gy is appropriate for local control of MALT lymphoma. RT is also an effective salvage therapy in cases of localized recurrence.
本研究旨在评估放射治疗（RT）对早期黏膜相关淋巴组织（MALT）淋巴瘤的疗效。
回顾性分析接受RT治疗的IotaE期（n = 48）和首都PE、西里尔E期（n = 2）MALT淋巴瘤患者。原发肿瘤起源于胃20例，眼眶9例，结膜或眼睑及腮腺各6例，其他部位9例。RT总剂量中位数为32Gy（范围25.6 - 50Gy）。中位随访时间为50个月。
尽管无论总剂量如何，任何患者的RT野内均未出现疾病复发，但7例患者在RT野外出现疾病复发。由于所有复发均为局限性，对每次复发均进行了挽救性RT，且在野内实现了完全缓解且无复发。5年总生存率、局部控制率和无进展生存率分别为96.6%、100%和82.2%。
25 - 30Gy的总剂量适用于MALT淋巴瘤的局部控制。RT在局限性复发的病例中也是一种有效的挽救性治疗方法。
